Adamas Pharmaceuticals, Inc. (ADMS): Price and Financial Metrics


Adamas Pharmaceuticals, Inc. (ADMS): $5.38

0.19 (+3.66%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ADMS POWR Grades


  • ADMS scores best on the Value dimension, with a Value rank ahead of 77.32% of US stocks.
  • ADMS's strongest trending metric is Growth; it's been moving down over the last 31 weeks.
  • ADMS's current lowest rank is in the Momentum metric (where it is better than 5.04% of US stocks).

ADMS Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for ADMS is 13.36 -- better than 97.73% of US stocks.
  • ADMS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 2.59% of US stocks.
  • Adamas Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -29.92%, greater than the shareholder yield of merely 8.48% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Adamas Pharmaceuticals Inc are USWS, XTNT, ALIM, AINC, and CVU.
  • Visit ADMS's SEC page to see the company's official filings. To visit the company's web site, go to www.adamaspharma.com.

ADMS Price Target

For more insight on analysts targets of ADMS, see our ADMS price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $8.79 Average Broker Recommendation 1.61 (Moderate Buy)

ADMS Stock Price Chart Interactive Chart >

Price chart for ADMS

ADMS Price/Volume Stats

Current price $5.38 52-week high $9.15
Prev. close $5.19 52-week low $2.43
Day low $5.22 Volume 717,600
Day high $5.53 Avg. volume 566,384
50-day MA $5.20 Dividend yield N/A
200-day MA $4.85 Market Cap 222.55M

Adamas Pharmaceuticals, Inc. (ADMS) Company Bio


Adamas Pharmaceuticals is a specialty pharmaceutical company driven to improve the lives of those affected by chronic disorders of the central nervous system. The company was founded in 2000 and is based in Emeryville, California.


ADMS Latest News Stream


Event/Time News Detail
Loading, please wait...

ADMS Latest Social Stream


Loading social stream, please wait...

View Full ADMS Social Stream

Latest ADMS News From Around the Web

Below are the latest news stories about Adamas Pharmaceuticals Inc that investors may wish to consider to help them evaluate ADMS as an investment opportunity.

Adamas Announces New Employment Inducement Grant

EMERYVILLE, Calif., Jun 11, 2021--Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted three new employees restricted stock units to acquire 22,500 shares of the company’s common stock. The restricted stock units vest over three years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the

Yahoo | June 11, 2021

New Data Analysis Supports GOCOVRI as an Important Treatment for Motor Complications for People With Parkinson’s Disease

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the publication of a new data analysis titled, "Effects of GOCOVRI® (amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson’s disease and dyskinesia" in the peer-reviewed journal of Neurology and Therapy. The publication highlights a post-hoc da

Yahoo | June 10, 2021

Adamas to Present at Upcoming June Conferences

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced that the organization will be participating in two upcoming June conferences:

Yahoo | May 27, 2021

Cigna (CI) to Post Q1 Earnings: Will It Deliver a Beat?

Cigna (CI) Q1 results are likely to reflect better revenues but a weak bottom line.

Yahoo | May 6, 2021

Adamas Launches "Picture More Time" Campaign to Raise Awareness and Understanding of the Impact of OFF Time and Dyskinesia for People With Parkinson’s Disease and Care Partners

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced the launch of "Picture More Time," a disease education campaign focused on raising awareness and understanding of OFF time and dyskinesia and the emotional and social impacts these motor complications have on people with Parkinson’s disease (PD) and their care partners.

Yahoo | April 27, 2021

Read More 'ADMS' Stories Here

ADMS Price Returns

1-mo 3.07%
3-mo -4.44%
6-mo 9.13%
1-year 91.46%
3-year -79.46%
5-year -70.21%
YTD 24.25%
2020 14.25%
2019 -55.62%
2018 -74.80%
2017 100.53%
2016 -40.32%

Continue Researching ADMS

Here are a few links from around the web to help you further your research on Adamas Pharmaceuticals Inc's stock as an investment opportunity:

Adamas Pharmaceuticals Inc (ADMS) Stock Price | Nasdaq
Adamas Pharmaceuticals Inc (ADMS) Stock Quote, History and News - Yahoo Finance
Adamas Pharmaceuticals Inc (ADMS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9134 seconds.